Clinical trials: Infliximab
Osteoarthritis of the Knee
Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab
The purpose of this study is to determine if an anti-inflammatory drug, called infliximab, will reduce inflammation in the synovial lining in patients with an early stage of osteoarthritis of the knee.
- Trial name
- NCT01144143
- Testing
- Infliximab, Standard of Care: Methylprednisolone acetate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Herbert Lindsley, MD
Rheumatoid Arthritis
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
- Trial name
- NCT00095147
- Testing
- Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB
- Where
- 76 sites in United States, Argentina and 15 more
- Volunteers
- 431 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection
- Trial name
- PARTNER (NCT00512278)
- Testing
- Infliximab
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Nizar Zein
Depression
Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression
The main purpose of this study is to examine the effects of infliximab on measures related to depression symptoms. Infliximab is also known by its brand name Remicade.
- Trial name
- NCT03006393
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Rheumatoid Arthritis
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis
Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with…
- Trial name
- NCT00207714
- Testing
- Golimumab, MTX, Infliximab
- Volunteers
- 172 people
- Sponsor
- Centocor, Inc.
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Spondylitis, Ankylosing, Arthritis, Rheumatoid
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
The purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.
- Conditions
- Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic
- Trial name
- NCT00760669
- Testing
- Infliximab; observational study, Methotrexate; observational study
- Volunteers
- 1,061 people
- Sponsor
- Janssen Korea, Ltd., Korea
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects
The purpose of this study is to compare the pharmacokinetics, safety, tolerability and immunogenicity of SB2 and Remicade (EU sourced Remicade and US sourced Remicade) in healthy subjects.
- Trial name
- NCT01922336
- Testing
- SB2, EU Remicade, US Remicade
- Where
- Germany
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Crohn Disease
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents.
- Trial name
- REMODEL (NCT04974099)
- Testing
- RoadMAB precision dashboard, Infliximab precision dosing
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Ulcerative Colitis
European Safety Registry in Ulcerative Colitis (P04808)
This is a prospective, safety surveillance registry in participants with moderate-to-severe active ulcerative colitis (UC).
- Trial name
- OPUS (NCT00705484)
- Testing
- infliximab, Standard Therapy
- Volunteers
- 2,239 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis
ASART-1 clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety profile of BCD-055 (infliximab manufactured by JSC BIOCAD, Russia) and Remicade when used as multiple IV…
- Trial name
- NCT02359903
- Testing
- Infliximab (BCD-055), Infliximab (Remicade)
- Where
- 6 sites in Belarus, Russia
- Volunteers
- 90 people
- Sponsor
- Biocad
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Immune Modulators for Treating COVID-19
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- ACTIV-1 IM (NCT04593940)
- Testing
- Infliximab, Abatacept, Remdesivir
- Where
- 91 sites in United States, Argentina and 3 more
- Volunteers
- 1,971 people
- Sponsor
- Daniel Benjamin
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)
This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study.
- Trial name
- REQUEST (NCT00741104)
- Testing
- Infliximab
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Rheumatoid Arthritis
RESTART C0168Z05 Rheumatoid Arthritis Study
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition…
- Trial name
- NCT00714493
- Testing
- Infliximab
- Where
- 76 sites in United States, Austria and 8 more
- Volunteers
- 203 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Reperfusion Injury
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
The purpose of this study is to establish the effectiveness of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol…
- Trial name
- CAPITL (NCT02251041)
- Testing
- Antithrombin-III, Infliximab, Apotransferrin
- Where
- Belgium
- Volunteers
- 143 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven